Non-FDG PET tracers in oncology: the story so far
The role of radionuclide molecular imaging in oncology with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (18F-FDG) is well established. There is ample evidence to support the role of 18F-FDG PETCT in various clinical scenarios and cancer types. However, there has been a phenomenal expansion in non-FDG PET radiopharmaceuticals for use in clinical oncology. 68Ga is a well established radionuclide […]
Dr Gopinath Gnanasegaran
Royal Free London NHS Foundation Trust